Method Transfer from an Agilent 1260 Infinity LC to an Agilent 1260 Infinity II LC

Significance of the Topic

The transfer of validated analytical methods between different liquid chromatography instruments is critical for maintaining regulatory compliance and data integrity in pharmaceutical and other industries. Ensuring seamless instrument-to-instrument consistency minimizes downtime, reduces revalidation efforts, and supports efficient laboratory workflows.

Objectives and Overview of the Study

This study aims to demonstrate the proof of equivalency when transferring a beta-blocker analysis method from an Agilent 1260 Infinity LC to an Agilent 1260 Infinity II LC. Key goals include comparing retention times and resolution across instruments and adapting the method to UHPLC conditions for faster analysis and reduced solvent consumption.

Applied Instrumentation

• Agilent 1260 Infinity LC modules including binary pump, standard degasser, high-performance autosampler with thermostat, thermostatted column compartment, and diode array detector.
• Agilent 1260 Infinity II LC modules including binary pump, multisampler with cooling option, multicolumn thermostat, and diode array detector HS.
• Columns used: InfinityLab Poroshell 120 EC-C18 (4.6×100 mm, 2.7 µm and 3.0×50 mm, 2.7 µm).
• Software: Agilent OpenLAB CDS Version 2.1 for instrument control and data analysis.
• Chemicals: LC-grade acetonitrile, ultrapure water, trifluoroacetic acid, and beta-blocker standards (metoprolol, pindolol, propranolol, timolol).

Methodology

The LC method employed a gradient from 10 to 50% acetonitrile (both phases containing ~0.1% TFA) over 16 minutes at 1.5 mL/min and 25 °C, with a 10 µL injection. UV detection was set at 275 nm (4 nm bandwidth) with reference at 380 nm. For UHPLC speed-optimized conditions, a shorter column (3.0×50 mm) and faster gradient (0–50% B in 2.67 minutes) at 1.92 mL/min were used, reducing sample volume to 4.25 µL and total cycle time to under 4 minutes.

Main Results and Discussion

Retention time precision on both instruments was excellent (RSD ≤0.07% on 1260 Infinity LC, ≤0.03% on 1260 Infinity II LC), with maximum deviation between instruments below 1.0%. Peak resolution values were essentially identical, confirming seamless method transfer. Under UHPLC conditions, run time decreased by 83% and solvent usage by 79% without compromising separation quality.

Benefits and Practical Application of the Method

• Regulatory compliance through validated instrument equivalency.
• Reduced revalidation effort and faster deployment of methods on new systems.
• Significant time and solvent savings using UHPLC-optimized conditions.
• Flexibility to expand the workflow to other small-molecule analyses.

Future Trends and Possibilities for Use

The demonstrated approach can be extended to various pharmaceutical compounds and other regulated industries. Increased adoption of UHPLC will drive further efficiency gains. Integration with advanced software platforms and automated data reporting will support digital laboratories and reinforce green chemistry practices.

Conclusion

The successful transfer of a beta-blocker LC method from Agilent 1260 Infinity to 1260 Infinity II LC confirmed equivalent retention times and resolution, while UHPLC adaptation delivered substantial time and solvent savings. This work underscores the robustness of Agilent InfinityLab workflows and their suitability for high-throughput pharmaceutical analysis.

Reference

• Agilent 1290 Infinity with ISET, Agilent Technologies User Manual, part number G4220-90314, 2015.
• Caban et al. Comparative study of β-blocker derivatization for GC and GC-MS, Journal of Chromatography A, 2011, 1218, 8110–8122.
• Lee et al. Determination of β-blockers in sewage by SPE and LC-MS/MS, Journal of Chromatography A, 2007, 1148, 158–167.
• Kumar and Park. Fast chiral β-blocker separations by capillary electrochromatography, Journal of Chromatography A, 2011, 1218, 5369–5373.